Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18728345 | 0.92 | CYP4F2 (0.46) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL963907 | 0.90 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL6187331 | 0.89 | CYP4F2 (0.46) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 | |
| SCHEMBL415499 | 0.87 | MEN1 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 | |
| SCHEMBL390461 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL6188518 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL606159 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL26103503 | 0.87 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL20565162 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL2795230 | 0.87 | CYP4F2 (0.53) | USP2SMN1; SMN2CYP4F2CYP4A11PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| CN-110177786-B | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2021043077-A1 | SUBSTITUTED PYRAZINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-9266867-B2 | Piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-04-10 | — | — | US | disclosed |
| EP-2697219-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | Bioprojet (FR) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012140020-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511275-A1 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511275-A1 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2012-10-17 | — | — | EP | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | USP2 1667/4885SMN1; SMN2 3852/4885CYP4F2 3293/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | USP2 3655/4885SMN1; SMN2 646/4885CYP4F2 2728/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | USP2 1667/4885SMN1; SMN2 3852/4885CYP4F2 3293/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | USP2 1667/4885SMN1; SMN2 3852/4885CYP4F2 3293/4885 |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | USP2 3658/4885SMN1; SMN2 2387/4885CYP4F2 3913/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | USP2 3655/4885SMN1; SMN2 646/4885CYP4F2 2728/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | USP2 1667/4885SMN1; SMN2 3852/4885CYP4F2 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.